Which estrogen—estradiol or estrone—is preferred for menopausal hormone therapy, and what are the reasons for this preference?

Estradiol is Preferred Over Estrone for Menopausal Hormone Therapy

Estradiol is the preferred estrogen for menopausal hormone therapy (MHT), not estrone. Estradiol is the principal intracellular human estrogen and is substantially more potent than estrone at the receptor level 1. All major clinical guidelines and FDA-approved formulations focus on estradiol (or conjugated estrogens) as the therapeutic agent, while estrone is primarily recognized as a metabolite with unknown or potentially harmful biological effects.

Why Estradiol is Superior

Biological Potency and Safety Profile

Estradiol functions as the primary active estrogen in the body, while estrone represents a weaker metabolite. The 2015 Endocrine Society guidelines explicitly recommend estradiol tablets or conjugated estrogens as the standard oral preparations for MHT, noting they "alleviate climacteric symptoms in a dose-dependent fashion" 2. The FDA labeling for estradiol confirms it is "substantially more potent than its metabolites, estrone and estriol at the receptor level" 1.

Concerning Effects of Elevated Estrone

The biological effects of elevated estrone levels remain unknown and potentially problematic 2. Recent research reveals troubling findings:

• Estrone promotes cancer metastasis: Unlike estradiol, estrone activates epithelial-to-mesenchymal transition (EMT) genes, stimulates breast cancer invasion, and promotes metastasis to lung, bone, and liver in ER+ breast cancer models 3
• Estrone is pro-inflammatory: Estrone cooperates with NF-κB to stimulate inflammation and increases cancer stem cell markers, while estradiol opposes these effects 4
• Higher estrone associates with worse outcomes: Elevated expression of enzymes that convert estradiol to estrone (HSD17B14) correlates with earlier metastasis and poorer prognosis 3, 4

Route of Administration Matters Critically

Transdermal Estradiol is Preferred Over Oral

Transdermal estradiol delivery (patches, gels, sprays) should be the first-line route of administration for most women, particularly those with cardiovascular or thrombotic risk factors 2.

Key advantage: Oral estradiol produces 5-fold higher circulating estrone levels and 10- to 20-fold higher estrone sulfate levels compared to transdermal administration at comparable doses 2. This massive difference persists with long-term use—oral estradiol produces estrone sulfate levels of 38.8 ng/mL versus only 1.8-3.2 ng/mL with transdermal patches 5.

Specific Clinical Scenarios Favoring Transdermal Estradiol

Transdermal estradiol is preferable for women with 2:

• VTE risk (supported by meta-analysis)
• Hypertension
• Hypertriglyceridemia
• Obesity or metabolic syndrome
• Diabetes
• History of gallbladder disease

The transdermal route avoids first-pass hepatic metabolism, eliminating the procoagulant effects and increases in inflammatory markers (C-reactive protein) seen with oral estrogens 2.

Practical Prescribing Algorithm

Starting Therapy

1. Choose estradiol formulation (not estrone-based products)
2. Prefer transdermal route unless contraindicated
3. Start with lowest effective dose:
   • Transdermal patches: 0.025-0.05 mg/day
   • Oral micronized estradiol: 0.5-1 mg/day (lower than WHI doses)
4. Titrate upward based on symptom response 2

Special Populations

• Younger women with surgical menopause or POI: May require higher starting doses (e.g., transdermal 100 µg) due to accustomed higher baseline estradiol levels, then taper as tolerated 2
• Women without a uterus: Estrogen alone (no progestogen needed) 2
• Women with intact uterus: Must add progestogen for endometrial protection 2

Critical Caveats

Monitoring Considerations

• Do not routinely measure estradiol levels except when symptoms fail to improve with escalating doses, particularly after switching from oral to transdermal 2
• Substantial interindividual variation exists in estradiol absorption, especially with gels and in younger women 6
• 24.84% of women on highest licensed transdermal doses have subtherapeutic levels (<200 pmol/L), suggesting some women may need off-label dosing 6

The Estrone Problem with Oral Therapy

While oral micronized estradiol is FDA-approved and effective, the unknown biological effects of markedly elevated estrone and estrone sulfate represent a theoretical concern 2. Given emerging evidence linking estrone to pro-inflammatory effects and cancer progression 3, 4, the transdermal route's avoidance of this metabolic profile provides additional rationale for its preference.

No Head-to-Head Outcome Trials

Important limitation: No existing randomized controlled trials with clinical outcomes directly compare transdermal versus oral estradiol 2. The preference for transdermal is based on pharmacokinetic differences, surrogate markers, and meta-analyses of VTE risk—not definitive outcome data.

Bottom Line

Prescribe estradiol (not estrone) via transdermal delivery as first-line MHT for most postmenopausal women. Use the lowest effective dose, add progestogen if the uterus is intact, and reassess need for continued therapy every 3-6 months 2, 1. Reserve oral estradiol for women who prefer it or cannot use transdermal formulations, recognizing this route produces substantially higher estrone metabolite levels of uncertain clinical significance.